PRELUDE THERAPEUTICS INC (PRLD)

Every figure this model derived for PRLD, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 151,757,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 154,898,000 AssetsCurrent 2026-06-30
current liabilities 38,042,000 LiabilitiesCurrent 2026-06-30
equity 133,733,000 StockholdersEquity 2026-06-30
ocf -33,255,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 22,424,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 8,294,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up PRLD on one particular measure came for.

RatioValue
cash operating margin-256.49
current ratio12.11
current ratio reported4.07
dilution pct1.52
fcf margin-148.3
operating margin-300.56
owner earnings margin-185.29
revenue growth220.34
revenue growth per share215.55
rule of 40-80.21
sbc pct revenue36.99

What to be careful about

What this model itself distrusts about PRLD's figures. Written by the derivation as it ran, not added afterwards.